Original paper
P34.07 Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer
Abstract
Osimertinib has a high response rate in untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients. However, currently there are no biomarkers to determine the efficacy of osimertinib. This study investigated whether BIM-γ mRNA expression in circulating tumor cells (CTCs) predicted a poor prognosis of osimertinib treatment in patients with EGFR mutation-positive...
Paper Details
Title
P34.07 Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer
Published Date
Mar 1, 2021
Journal
Volume
16
Issue
3
Pages
S417 - S418
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History